24 citations
,
November 1992 in “Journal of the American Academy of Dermatology” This report on a case of cutaneous lymphomatoid granulomatosis underscores the pivotal role dermatologists have in its early diagnosis, which could potentially improve the otherwise poor prognosis.
6 citations
,
February 2010 in “Journal of The American Academy of Dermatology” This case report details a 31-year-old woman with a subcutaneous nodule on her hand characterized by necrosis and lymphocytic infiltrate.
September 2013 in “Oncology Times” This article discusses the discontinuation of the Bexxar regimen for non-Hodgkin's lymphoma, noting that despite its effectiveness, it was under-prescribed due to marketing and development challenges without reporting new clinical results.
35 citations
,
October 2021 in “Journal of the European Academy of Dermatology and Venereology” This report describes two cases where a viral vector COVID-19 vaccine was associated with the recurrence of cutaneous lymphoma conditions that had been in remission.
1 citations
,
February 2009 in “Clinical and Experimental Dermatology” This study reports an improvement in lymphomatoid papulosis type A in a 52-year-old patient who concurrently used hormone-replacement therapy.
245 citations
,
October 2015 in “Nature medicine” The research found that hair follicle–derived cytokines, particularly IL-15 and IL-7, regulate skin-resident memory T cells and their role in both immune homeostasis and lymphoma in the skin.
11 citations
,
September 1999 in “Journal of the European Academy of Dermatology and Venereology” This review examines various immunomodulatory therapies for cutaneous lymphoma and notes that they are most effective in the disease's early stages.
9 citations
,
October 2008 in “British Journal of Dermatology” This case report describes a patient with primary cutaneous natural killer/T-cell lymphoma, nasal type, where monoclonal Epstein–Barr virus genome expansion was associated with terminal aggressive behavior after an indolent clinical course.
7 citations
,
September 2006 in “Clinical lymphoma & myeloma” This review discusses various treatment challenges and toxicities in patients with relapsed follicular lymphoma and suggests that novel therapies could improve outcomes by reducing exposure to harmful chemotherapy cycles.
2 citations
,
January 1990 in “Leukemia & Lymphoma” This study reported a 74% overall response rate for a new combination chemotherapy of mitoxantrone, etoposide, and prednisolone in patients with relapsed or refractory Hodgkin's disease or non-Hodgkin's lymphoma.
This review analyzed literature on primary cutaneous lymphomas involving the scalp, finding that scalp involvement in these cases often leads to non-scarring focal alopecia and may indicate more aggressive disease.
April 2020 in “Journal of the Endocrine Society” This case report details an atypical presentation of Hodgkin's lymphoma in an 87-year-old man, where severe hypercalcemia and mental status changes prompted further investigation and diagnosis.
February 2024 in “Deleted Journal” This case study in a Labrador dog diagnosed with cutaneous lymphoma reports that treatment using the modified Wisconsin Madison protocol led to an uneventful recovery, despite the occurrence of vincristine-associated ileus, which was successfully treated with neostigmine.
April 2019 in “Journal of Investigative Dermatology” This study reported that in mycosis fungoides and Sezary syndrome, there is male predominance and younger age of presentation in early-stage disease, with significant data collection efforts supporting biomarker identification.
April 2018 in “Veterinary Pathology” This study describes a form of lymphocytic mural folliculitis in tigers causing hair loss, concluding it may represent a nonspecific hypersensitivity reaction distinct from T-cell lymphoma.
September 2016 in “Journal of Dermatological Science” This research suggests that hair follicle-derived cytokines IL-7 and IL-15 are crucial for maintaining resident memory T cells in the skin, which may be relevant for diseases like cutaneous T cell lymphoma.
209 citations
,
March 1989 in “Journal of The American Academy of Dermatology” This study found that recombinant human leukocyte interferon alfa-2a achieved a 64% overall antitumor response rate in patients with early and advanced cutaneous T cell lymphoma and was generally well-tolerated.
107 citations
,
December 2003 in “Dermatologic Therapy” This paper reviews the use of interferons, particularly alfa interferon, in treating cutaneous T-cell lymphoma, noting its substantial efficacy both alone and in combination therapies with predictable, generally well-tolerated side effects.
39 citations
,
May 2004 in “Clinics in Dermatology” This article reviews treatment options for cutaneous T-cell lymphoma, including skin-directed therapies and aggressive treatments for advanced cases, but reports no new clinical results.
18 citations
,
July 2016 in “Journal of The American Academy of Dermatology” This study reported that both primary and secondary cutaneous follicle center lymphomas can present with atypical scalp or forehead lesions, leading to potential misdiagnosis as other skin conditions.
15 citations
,
January 2014 in “Dermatology” This case report describes alopecia universalis-like hair loss occurring in two patients with cutaneous T cell lymphoma, providing clinical, dermoscopic, and pathologic features to help differentiate it from alopecia areata universalis.
11 citations
,
October 2001 in “Dermatologic Clinics” In this study, subcutaneous recombinant human IL-12 showed a 43% partial response rate in early-stage mycosis fungoides patients refractory to previous treatments, with generally mild to moderate adverse events reported.
10 citations
,
April 2014 in “Molecular and Clinical Oncology” This case report describes a 46-year-old male whose alopecia areata preceded and resolved with treatment for stage IVB classical Hodgkin's lymphoma, highlighting AA as a potential indicator of underlying malignancy, although such cases are rare and not well-characterized.
9 citations
,
January 2018 in “Acta Clinica Croatica” This review suggests that bendamustine, alone or in combination, shows effectiveness in treating indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia, with recent studies highlighting its benefits especially in combination therapies, while balancing efficacy with a favorable toxicity profile.
6 citations
,
July 2015 in “European Journal of Dermatology” Stopping methotrexate might reverse lymphoma-like conditions in some patients.
5 citations
,
June 2001 in “Annals of Internal Medicine” This report describes a case where rituximab provided durable remission in a patient with refractory aggressive diffuse B-cell lymphoma that was unresponsive to prior chemotherapy.
3 citations
,
January 2019 in “Skin appendage disorders” This case report describes a patient with primary cutaneous follicle center lymphoma who developed an alopecic atrophic patch potentially due to pressure, following rituximab treatment.
2 citations
,
December 2021 in “Journal of Veterinary Medical Science” This case report found that adding lokivetmab to prednisolone treatment improved and maintained remission of pruritus in a dog with cutaneous epitheliotropic lymphoma.
1 citations
,
September 2024 in “Porto Biomedical Journal” This case report illustrates the diagnostic challenges and importance of early detection in primary vitreoretinal lymphoma, highlighting a successful treatment outcome with systemic chemotherapy in preventing CNS progression.
1 citations
,
April 2019 in “JAAD case reports” This case report presents a rare manifestation of secondary cutaneous B-cell lymphoma as erythematous macules coalescing into reticular patches on the scalp and forehead.